Kaletra (AbbVie Inc.)


Welcome to the PulseAid listing for the Kaletra drug offered from AbbVie Inc.. This HIV Protease Inhibitors [MoA],Protease Inhibitor [EPC],P-Glycoprotein Inhibitors [MoA],Cytochrome P450 3A Inhibitors [MoA],Organic Anion Transporting Polypeptide 1B1 Inhibitors [MoA],UDP Glucuronosyltransferases Inducers [MoA],HIV Protease Inhibitors [MoA],Cytochrome P450 3A Inhibitor [EPC],Protease Inhibitor [EPC],Cytochrome P450 3A Inhibitors [MoA],Cytochrome P450 2D6 Inhibitors [MoA],Cytochrome P450 2C19 Inducers [MoA],Cytochrome P450 3A Inducers [MoA],P-Glycoprotein Inhibitors [MoA],Breast Cancer Resistance Protein Inhibitors [MoA],Cytochrome P450 3A4 Inhibitors [MoA],Cytochrome P450 1A2 Inducers [MoA],Cytochrome P450 2C9 Inducers [MoA],Cytochrome P450 2B6 Inducers [MoA] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
LABELER NAME / MANUFACTURER: AbbVie Inc.
NON-PROPRIETARY NAME: Lopinavir and Ritonavir
SUBSTANCE NAME: LOPINAVIR; RITONAVIR
TYPE: HUMAN PRESCRIPTION DRUG
PHARMA CLASS: HIV Protease Inhibitors [MoA],Protease Inhibitor [EPC],P-Glycoprotein Inhibitors [MoA],Cytochrome P450 3A Inhibitors [MoA],Organic Anion Transporting Polypeptide 1B1 Inhibitors [MoA],UDP Glucuronosyltransferases Inducers [MoA],HIV Protease Inhibitors [MoA],Cytochrome P450 3A Inhibitor [EPC],Protease Inhibitor [EPC],Cytochrome P450 3A Inhibitors [MoA],Cytochrome P450 2D6 Inhibitors [MoA],Cytochrome P450 2C19 Inducers [MoA],Cytochrome P450 3A Inducers [MoA],P-Glycoprotein Inhibitors [MoA],Breast Cancer Resistance Protein Inhibitors [MoA],Cytochrome P450 3A4 Inhibitors [MoA],Cytochrome P450 1A2 Inducers [MoA],Cytochrome P450 2C9 Inducers [MoA],Cytochrome P450 2B6 Inducers [MoA]
ROUTE: ORAL
DOSAGE FORM: TABLET, FILM COATED
MARKETING CATEGORY NAME: NDA
START MARKETING DATE: 2010-06-18
END MARKETING DATE: 0000-00-00


Kaletra HUMAN PRESCRIPTION DRUG Details:

Item DescriptionKaletra from AbbVie Inc.
LABELER NAME: AbbVie Inc.
DEA SCHEDULE:
ACTIVE STRENGTH: 100; 25(mg/1; mg/1)
START MARKETING DATE: 2010-06-18
END MARKETING DATE: 0000-00-00
PRODUCT ID: 0074-0522_3f1cb62c-b0a7-e1fc-b2ff-88901b1ad32a
PRODUCT NDC: 0074-0522
APPLICATION NUMBER: NDA021906

Other LOPINAVIR; RITONAVIR Pharmaceutical Manufacturers / Labelers:

Manufacturer / LabelerProprietary Name
AbbVie Inc.Kaletra
Cardinal HealthKaletra
Dispensing Solutions, Inc.Kaletra
DOH CENTRAL PHARMACYKaletra
HHS/Program Support Center/Supply Service CenterKaletra
Lannett Company, Inc.Lopinavir-Ritonavir
PD-Rx Pharmaceuticals, Inc.Kaletra
Physicians Total Care, Inc.Kaletra
Rebel Distributors CorpKaletra
REMEDYREPACK INC.Kaletra